Table 3 Incidence of adverse events associated with traditional NSAIDs or iCOX2 compared to placebo in patients with axSpA: meta-analysis of randomized clinical trials

Adverse events

35.6% vs 36.4% (PbO)

RR=1.08 (0.93 to 1.25)

54.6% vs 46.4% (PbO)

RR=1.22 (0.93 to 1.62)

Severe adverse events

1% vs 0.6% (PbO)

RR=1.71 (0.37 to 8.01)

0.6% vs 0.6% (PbO)

RR=0.96 (0.17 to 5.53)

Gastrointestinal adverse events

18% vs 9.5% (PbO)

RR=1.92 (1.41 to 2.61)

17.7% vs 7.5% (PbO)

RR=2.55 (1.92 to 4.95)

Discontinuation due to adverse events

5% vs 5.5% (PbO)

RR=0.76 (0.48 to 1.22)

4.6% vs 3.4% (PbO)

RR=2.14 (0.36 to 12.56)